What question did this study set out to answer?

To determine the effect of intensive lipid-lowering therapy with atorvastatin on early recurrent ischemic events in patients with acute coronary syndrome.

April 4, 2001JAMA

Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial

View Full Paper

Ask AI

Bookmark

Why the study?

Does atorvastatin 80 mg/d reduce recurrent ischemic events in patients with acute coronary syndrome?

Population

patients with acute coronary syndrome

Design

RCT, Randomized

Follow-up

16 weeks

Authors

GSGregory G. SchwartzPreventive Cardiology

Discussion

Member takes

Implication

Supports early high-dose atorvastatin initiation in ACS; confirms benefit of intensive lipid-lowering in the acute phase.

Key Points

To determine the effect of intensive lipid-lowering therapy with atorvastatin on early recurrent ischemic events in patients with acute coronary syndrome.
Randomized controlled trial (the MIRACL study) evaluating atorvastatin administered at 80 mg/day in patients with acute coronary syndrome.
Follow-up duration assessed clinical outcomes during the first 16 weeks following the index event.
Atorvastatin (80 mg/day) reduced recurrent ischemic events over the 16-week follow-up period compared to control.
The treatment effect was primarily driven by a reduction in recurrent symptomatic ischemia requiring rehospitalization.

Structured PICO

Does atorvastatin 80 mg/d reduce recurrent ischemic events in patients with acute coronary syndrome?

Population

patients with acute coronary syndrome

Intervention

atorvastatin, 80 mg/d

Outcome

recurrent ischemic eventscomposite

Early initiation of high-dose atorvastatin (80 mg/d) in patients with acute coronary syndrome reduces recurrent ischemic events within 16 weeks.

Cite This Study

Gregory G. Schwartz (2001) studied this question.

synapsesocial.com/papers/69dc32494f901957bec0fb70 https://doi.org/10.1001/jama.285.13.1711

Topics

PCSK9 inhibitors Statin therapy

View Full Paper

Ask AI

Bookmark

Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled Trial

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider